Catalent And NewMarket Pharmaceuticals To Develop Better Treatments




Catalent Pharma Solutions and NewMarket Pharmaceuticals LLC Partner to Develop Better Treatments for Production and Companion Animals

Somerset, NJ,  February 16, 2012 – Catalent Pharma Solutions, a leading global drug delivery technology company, and NewMarket Pharmaceuticals LLC have entered into an agreement to jointly formulate and develop a portfolio of products for treating production and companion animals using Catalent’s proprietary, market-leading Zydis® fast-dissolve technology and NewMarket’s DSI™ platform (Direct Systemic Introduction, patent pending). 

NewMarket Pharmaceuticals is currently developing five drugs that will combine Catalent’s Zydis® fast-dissolve and their own DSI™ technologies, initially including NSAIDs, beta agonists, proton pump inhibitors, and behavior modifiers across a variety of species including horses, dogs, and cattle, with plans to expand the range in other classes.  These new animal health products are expected to provide significant advantages over existing formulations currently used across a spectrum of indications for companion animals, equine, and production animals.

Mark Ridall, CEO of NewMarket Pharmaceuticals, states that, “These easy-to-use formulations could revolutionize the way we treat animals by providing for a simple, efficient, accurate method of treatment without the use of needles.”

“This partnership with NewMarket Pharmaceuticals demonstrates not only our commitment to provide more products and better treatments to our customers, but also signifies the versatile benefits that our Zydis® fast-dissolve technology continues to deliver,” stated Paul Jenkins, Global VP of Catalent’s ODT business.

To learn more about Catalent’s modified release technologies, please visit www.catalent.com/zydis .

About Catalent

From drug and biologic development services to delivery technologies to supply solutions, Catalent Pharma Solutions has the deepest expertise, the broadest offerings and the most unique technologies in the industry. With over 75 years of experience, Catalent helps customers get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and packaging solutions. Catalent employs approximately 8,000 people at 24 facilities worldwide and in fiscal year 2010 generated more than $1.7 billion in annual revenue. Catalent is headquartered in Somerset, NJ.

more products. better treatments. reliably supplied.™
About NewMarket Pharmaceuticals LLC

NewMarket Pharmaceuticals was founded with the purpose of modernizing drug delivery systems for the treatment of animals.  The company has identified a means by which established drugs that have proven safety and efficacy profiles, but exist in outdated or inefficient delivery systems, can be reformulated and administered to animals in a faster, safer, easier and more accurate manner that has the potential to dramatically expand the market for these drugs.  Headquartered in Princeton, NJ, NewMarket uses state of the art formulation technology to achieve these goals.  For more information, visit www.newmarketpharma.com.

Zydis® is a registered trademark of Catalent Pharma Solutions, Inc.
DSI™ (Direct Systemic Introduction) is a trademark of NewMarket Pharmaceuticals LLC